Antifibrotic Effects of CXCL9 and Its Receptor CXCR3 in Livers of Mice and Humans
Open Access
- 31 July 2009
- journal article
- Published by Elsevier BV in Gastroenterology
- Vol. 137 (1), 309-319.e3
- https://doi.org/10.1053/j.gastro.2009.03.053
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Insertion of the CXC chemokine ligand 9 (CXCL9) into the mouse hepatitis virus genome results in protection from viral-induced encephalitis and hepatitisVirology, 2008
- Chemokines in the immunopathogenesis of hepatitis C infectionHepatology, 2008
- Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis CHepatology, 2008
- Mechanisms of Hepatic FibrogenesisGastroenterology, 2008
- Common and rare variants in multifactorial susceptibility to common diseasesNature Genetics, 2008
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- The role of CXC chemokines in pulmonary fibrosisJCI Insight, 2007
- CXCR3-Dependent Recruitment of Antigen-Specific T Lymphocytes to the Liver during Murine Cytomegalovirus InfectionJournal of Virology, 2007
- Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signalingJCI Insight, 2006
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004